Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | TACR3 | P29371 | 6/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8846391 | 0.99 | ATM (0.44) | ATMTMEM97SIGMAR1TACR3ACHE | |
| SCHEMBL4834581 | 0.85 | SLC6A4 (0.47) | CHRM2CHRM1SLC6A4OPRM1 | |
| Hydrochloric Acid SCHEMBL7372762 | 0.84 | SLC6A4 (0.46) | CHRM2CHRM1SLC6A4OPRM1 | |
| SCHEMBL4837893 | 0.81 | CHRM2 (0.54) | SIGMAR1CHRM2CHRM1SLC6A4OPRM1 | |
| SCHEMBL649003 | 0.81 | SLC6A4 (0.45) | CHRM2CHRM1SLC6A4OPRM1 | |
| Hydrochloric Acid SCHEMBL7368877 | 0.80 | SLC6A4 (0.44) | CHRM2CHRM1SLC6A4OPRM1 | |
| SCHEMBL4831862 | 0.80 | SLC6A4 (0.44) | CHRM2CHRM1SLC6A4OPRM1 | |
| Hydrochloric Acid SCHEMBL8529509 | 0.80 | CHRM2 (0.53) | CHRM2CHRM1SLC6A4OPRM1 | |
| Fumaric Acid SCHEMBL8846236 | 0.80 | SLC6A4 (0.40) | CHRM2CHRM1SLC6A4 | |
| Fumaric Acid SCHEMBL8846221 | 0.80 | SLC6A4 (0.40) | CHRM2CHRM1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407990-B2 | Therapeutic Agents | KNOLL GMBH (DE) | 2008-08-05 | — | — | US | claimed |
| US-20070129445-A1 | Therapeutic Agents | KNOLL GMBH (DE) | 2007-06-07 | — | — | US | claimed |
| US-6974840-B1 | Therapeutic agents | KNOLL GMBH (DE) | 2005-12-13 | — | — | US | claimed |
| US-20050182141-A1 | Therapeutic agents | LUSCOMBE GRAHAM P (GB) | 2005-08-18 | — | — | US | claimed |
| EP-0715620-B1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | KNOLL AG (DE) | 1998-10-28 | — | — | EP | claimed |
| EP-0715620-A1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | Knoll AG (DE) | 1996-06-12 | — | — | EP | claimed |
| WO-1994026704-A1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | THE BOOTS COMPANY PLC (GB) | 1994-11-24 | — | — | WO | claimed |
| US-7407990-B2 | Therapeutic Agents | KNOLL GMBH (DE) | 2008-08-05 | — | — | US | disclosed |
| US-20070129445-A1 | Therapeutic Agents | KNOLL GMBH (DE) | 2007-06-07 | — | — | US | disclosed |
| US-6974840-B1 | Therapeutic agents | KNOLL GMBH (DE) | 2005-12-13 | — | — | US | disclosed |
| US-20050182141-A1 | Therapeutic agents | LUSCOMBE GRAHAM P (GB) | 2005-08-18 | — | — | US | disclosed |
| US-5652271-A | ANTIDEPRESSANTS, NERVOUS SYSTEM DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 1997-07-29 | — | — | US | disclosed |
| EP-0715620-A1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | Knoll AG (DE) | 1996-06-12 | — | — | EP | disclosed |
| WO-1994026704-A1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | THE BOOTS COMPANY PLC (GB) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129445-A1 | Therapeutic Agents | OPRM1, CNR1, SIGMAR1 | ATM 3354/4885TMEM97 161/4885SIGMAR1 3/4885 |
| US-20050182141-A1 | Therapeutic agents | OPRM1, CNR1, SIGMAR1 | ATM 3519/4885TMEM97 176/4885SIGMAR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.